ANTXR1 and neoplasm: Preclinical studies involving the development of an immune response against different antigens overexpressed by TEC, such as bFGF, angiomotin, endoglin, Robo4, PDGFRβ, Tie-2, and tumor endothelial markers (TEM1 and TEM8) show that endothelial vaccination successfully reduces tumor growth in different tumor models, both in vitro and in vivo [100].